Industry groups critique new guidance for Medicare drug price negotiations in 2027

The Cen­ters for Medicare & Med­ic­aid Ser­vices pro­posed a num­ber of changes to its Medicare ne­go­ti­a­tion guid­ance on Fri­day, some of which would af­fect how the next round of drug prices is ne­go­ti­at­ed un­der the In­fla­tion Re­duc­tion Act. On Mon­day, in­dus­try groups PhRMA and BIO raised new con­cerns about the guid­ance.

For prices tak­ing ef­fect in 2027, CMS will se­lect up to 15 ther­a­pies for Medicare ne­go­ti­a­tions next year. The agency is still in the mid­dle of ne­go­ti­a­tions for the first round of 10 drugs set for 2026, but said it’s look­ing for ways to make the next round more “ef­fi­cient and ef­fec­tive.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.